PARIS/ZURICH/LONDON (Reuters) – Sanofi and Novartis mentioned on Wednesday they deliberate to extend stockpiles of medicines Britain in preparation for potential disruption if the UK crashes out of the European Union and not using a deal.
FILE PHOTO: The Sanofi emblem in entrance of the doorway of the French drug company’s headquarters in Paris, October 30, 2014. REUTERS/Christian Hartmann/File Photo
The transfer follows comparable motion by AstraZeneca , which mentioned final month it will enhance stockpiles of medicine that might be affected by Brexit by round 20 %.
Roche , the world’s largest maker of most cancers medicines, additionally mentioned it was taking “appropriate action” to overview its stock ranges in an effort to shield provides to sufferers.
Britain’s largest drugmaker, GlaxoSmithKline , mentioned final week it was taking steps to safe the availability of its medicines and vaccines forward of the UK’s departure from the EU, with out going into particulars.
Supplies of 1000’s of medicines are liable to disruption if Britain leaves the EU and not using a deal, forcing producers to arrange duplicate product testing and licensing preparations to make sure their medicine keep on the market.
More than 2,600 medicine have some stage of manufacture in Britain and 45 million affected person packs are equipped from the UK to different European international locations every month, whereas one other 37 million stream in the other way, trade figures present.
Leading drugmakers have lengthy been vocal of their considerations about Brexit and the necessity for the prescribed drugs sector to remain throughout the European regulatory system.
British lawmakers have additionally known as for an settlement that enables the nation to have continued participation within the European medicines regulatory framework, nevertheless it stays unclear how it will play out within the broader EU negotiations.
Sanofi mentioned it was assured its stockpiling measures would guarantee British sufferers had entry to its remedies after Britain leaves the EU, no matter whether or not a deal over its future relations with the bloc is in place.
“The uncertainty in the Brexit negotiations means that Sanofi has always been planning for a no deal scenario,” a spokesman with the French drugmaker mentioned in an emailed assertion.
“We have made arrangements for additional warehouse capacity in order to stockpile our products in the UK and increase UK-based resources to prepare for any changes to customs or regulatory processes.”
Novartis mentioned it deliberate to carry elevated inventories in Britain throughout its portfolio of medicines from each Novartis itself and Sandoz, the Swiss company’s generic medicine division.
“We have apprised officials and ministers of our preparedness plans and status, including plans to increase our UK inventory holding,” Novartis mentioned.
The European Medicines Agency has warned drugmakers they wanted to be prepared for a potential exhausting Brexit in 2019. It has additionally expressed “serious concerns” over the provision of some 108 medicines which can be manufactured completely within the UK.
Reporting by Matthias Blamont, Michael Shields and Ben Hirschler; Editing by Richard Lough and Jane Merriman